Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RNTX
Strong SellSinkerRein Therapeutics Inc. · Healthcare · United States · $66M · Avg Vol: $361K/d
2
StockRankGet insider-trade alerts
Q
21
V
24
M
14
P/E (TTM)
—
ROE
-96.4%
D/E
0.4x
Dividend %
—
COMPANY DESCRIPTION
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | — | -0.32 | -0.20 | -0.89 | -0.63 | — | -1.68 | -0.46 | -0.47 | — |
| Shares | — | 85.5M | 85.5M | 85.5M | 85.5M | 0.0% | 86.3M | — | — | — |
| Debt | 0.2M | 33.0K | 48.0K | 0 | — | -45.6% | — | — | — | — |
| Equity | — | 18.6M | 6.9M | 9.4M | -28.1M | -29.0% | — | — | — | — |
| Op CF | — | -24.9M | -19.8M | -22.3M | -19.4M | — | -18.8M | — | — | — |
| Inv CF | -35.9M | 26.5M | 16.2M | 0 | — | — | — | — | — | — |
| Fin CF | — | 0 | 15.8M | 17.8M | 9.8M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+1.7%
SMA 50SMA 200
Close
$0.781
RSI (14)
48.1
52W High
$2.18
From 52W High
0.4%
SCORE BREAKDOWN
Quality
21
ROIC
-122.0%5.1
ROE
-96.4%10.0
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-33.5%11.6
Piotroski
211.9
Int. Cover
—N/A
D/E Ratio
0.42x32.5
Current Ratio
4.27x67.6
Value
24
P/E (TTM)
—N/A
EV/EBITDA
-3.7x25.0
P/FCF
—N/A
P/B
7.5x17.1
P/S
—N/A
Div Yield
—N/A
Momentum
14
52W High %
36%10.6
RS 6M
-51%12.6
SMA 50/200
0.73x9.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$66M
P/E (Forward)
—
Gross Margin
0.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RNTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RNTX | Rein Therapeutics Inc.(you) | $66M | 2 | Strong Sell |
| EXOZ | eXoZymes, Inc. | $67M | 2 | Strong Sell |
| ESLA | Estrella Immunopharma, Inc. | $62M | 1 | Strong Sell |
| IBIO | iBio, Inc. | $68M | 3 | Strong Sell |
| ELTX | Elicio Therapeutics, Inc. | $75M | 2 | Strong Sell |
| 2257.HK | Sirnaomics Ltd. | $55M | 1 | Strong Sell |
| FLNA | Filana Therapeutics, Inc. | $58M | 4 | Strong Sell |
| GOSS | Gossamer Bio, Inc. | $83M | 2 | Strong Sell |
| HRTX | Heron Therapeutics, Inc. | $62M | 7 | Strong Sell |
| KALA | KALA BIO, Inc. | $63M | 7 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%